November 1, 2022
Fattening the bottom line
Not like we needed more evidence, but the results released this morning by Lilly just confirm what we already knew Mounjaro is off to a strong start and well on its way to becoming a mega blockbuster. The FDA granted the drug a fast-track designation for obesity which will set up another bout with their rival Novo Nordisk who reports tomorrow. While it’s early in the Mounjaro launch here are the things to look for going forward
1. Lilly made a point of noting that less than 10% of the scripts for Mounjaro were patients switching from . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.
